Diversifying CureVac

How RNA play CureVac aims to diversify shareholders to attract U.S. investors

CureVac AG’s most recent financing is another step toward diversifying the RNA company’s shareholder base to make it more attractive to U.S. investors.

On Nov. 8, CureVac raised $29.5 million in the second tranche of a private financing led

Read the full 394 word article

User Sign In